Travere director sells 3,250 shares under plan

Travere Therapeutics, Inc. director Timothy Coughlin reported an open-market sale of 3,250 shares of common stock at $43.49 per share.

Accepted by SEC EDGAR 05/19/2026 - 04:05 PM EDT

Filing Impact

(Neutral)

Filing Sentiment

(Negative)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

Travere Therapeutics, Inc. director Timothy Coughlin reported an open-market sale of 3,250 shares of common stock at $43.49 per share. The transaction took place on May 15, 2026 and was executed under a pre-arranged Rule 10b5-1 trading plan. After the sale, he directly holds 52,250 shares.

Insider Trade Summary 10b5-1

Net Seller: 3,250 shares

Net Sell 1 txn

Insider Coughlin Timothy

Role Director

Sold 3,250 shs ($141K)

Share of Position Sold 5.9%

Type	Security	Shares	Price	Value
Sale	Common Stock	3,250	$43.49	$141K

Holdings After Transaction: Common Stock — 52,250 shares (Direct)

Holdings Before and After: Common Stock, 55,500 to 52,250 shares (Direct)

Other Insiders: 8 other insiders reported open-market sales of this stock in the 30 days up to this filing.

Footnotes (1)

F1. This sale was made pursuant to a written plan adopted on November 19, 2025, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended.

Key Figures

Shares sold: 3,250 shares Sale price: $43.49 per share Shares held after sale: 52,250 shares +1 more

4 metrics

Shares sold 3,250 shares Open-market sale on May 15, 2026

Sale price $43.49 per share Common stock transaction

Shares held after sale 52,250 shares Post-transaction direct ownership

Transactions reported as sales 1 transaction Form 4 transaction summary

Key Terms

Rule 10b5-1(c), open-market sale, Securities Exchange Act of 1934

3 terms

Rule 10b5-1(c) regulatory

"plan adopted on November 19, 2025, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934"

Rule 10b5-1(c) is an SEC guideline that lets company insiders set up a written, pre-planned schedule to buy or sell their company stock when they are not in possession of material, nonpublic information. For investors, it matters because such plans can reduce the appearance of insider trading by separating decisions from inside knowledge—like putting your trades on autopilot—while also requiring scrutiny since pre-planned trades can still affect market confidence and share value.

open-market sale financial

"transaction_action": "open-market sale", "transaction_code_description": "Sale in open market or private transaction""

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

Securities Exchange Act of 1934 regulatory

"meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Travere Therapeutics (TVTX) disclose for Timothy Coughlin?

Travere Therapeutics director Timothy Coughlin disclosed selling 3,250 shares of common stock. The sale was an open-market transaction at $43.49 per share, and it was executed under a pre-arranged Rule 10b5-1 trading plan, indicating it was scheduled in advance.

At what price were the Travere Therapeutics (TVTX) shares sold in this Form 4?

The reported Travere Therapeutics shares were sold at $43.49 per share. This price reflects the execution level for the 3,250-share open-market transaction disclosed, providing investors a clear view of the director’s sale terms on May 15, 2026.

How many Travere Therapeutics (TVTX) shares does Timothy Coughlin hold after the sale?

Following the reported transaction, Timothy Coughlin directly holds 52,250 shares of Travere Therapeutics common stock. This post-transaction balance shows that he retains a substantial equity position in the company even after the 3,250-share open-market sale.

Was the Travere Therapeutics (TVTX) insider sale made under a Rule 10b5-1 plan?

Yes. The filing states the sale was made under a written plan adopted pursuant to Rule 10b5-1(c). Such plans pre-schedule trades, which means the timing of this 3,250-share sale was determined in advance rather than by a discretionary decision.

What type of transaction is reported in the Travere Therapeutics (TVTX) Form 4?

The Form 4 reports an open-market sale of common stock by a company director. It involves 3,250 shares sold at $43.49 per share, coded as transaction type “S,” which denotes a sale in the open market or a private transaction.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Coughlin Timothy

(Last)

(First)

(Middle)

C/O TRAVERE THERAPEUTICS, INC.

3611 VALLEY CENTRE DR., SUITE 300

(Street)

SAN DIEGO

CALIFORNIA

92130

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Travere Therapeutics, Inc. [ TVTX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/15/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	05/15/2026		S⁽¹⁾		3,250	D	$43.49	52,250	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. This sale was made pursuant to a written plan adopted on November 19, 2025, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended.

	/s/ Elizabeth E. Reed, Attorney-in-Fact	05/19/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR